NCT00156286View on ClinicalTrials.gov

Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

January 31, 2006

Study Completion Date

April 30, 2006

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Gleevec

Trial Locations (1)

48109

Univeristy of Michigan Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT00156286 - Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC | Biotech Hunter | Biotech Hunter